East Asian patients are known to have differing risks of thrombophilia and bleeding compared with white patients, but few have been included in phase III trials of P2Y12inhibitors. Therefore, the World Heart Federation has produced this evidence-based review and expert consensus statement to determine the antiplatelet treatment strategies that are most appropriate for East Asian patients with acute coronary syndrome or undergoing percutaneous coronary intervention.
- Glenn N. Levine
- Young-Hoon Jeong
- Sidney C. Smith Jr
